Daño renal con inmunotx para cancer...
Febrero 10, 2020
Immunotherapy-Related Nephrotoxicity Is Rare, But Can Be Serious
By Ed Susman
ORLANDO, Fla -- February 10, 2020 -- Immune-related acute kidney injury (AKI) occurs infrequently among patients being treated with immune checkpoint inhibitors for advanced cancers, according to a study presented here at the 2020 Clinical Immuno-Oncology Symposium.
In a database of nearly 2,000 patients, immune-related AKI occurred in 14 patients and 8 cases were severe enough to warrant referral to kidney specialists, reported Jonathan Sorah, MD, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
None of the 14 patients were treated with steroids, and kidney function returned to baseline parameters in 5 patients. Two other patients improved but kidney function did not reach baseline numbers. One patient failed to improve and another was required to go on dialysis.
"Early recognition is critically important to prevent the possibility of irreversible renal damage, requiring prompt initiation of corticosteroids and nephrology consult," said Dr. Sorah. "Although clinically-significant immune-related acute kidney injury is uncommon among patients treated with immune checkpoint inhibitors, it is still likely under-recognised due to many confounding factors. High clinical suspicion should exist in patients with pre-existing autoimmune disease or a history of other immune-related adverse effects."
Two of the patients with acute kidney injury had been diagnosed with an autoimmune disorder and 9 patients with immune-related AKI also had a history of immune-related adverse effects.
Patients diagnosed with immune-related AKI were mostly men. Of the patients, 6 were being treated for non-small-cell lung cancer, 3 for melanoma, and 5 for other cancers. All patients were treated between April 2014 and December 2018. The etiology of the acute kidney injury was determined by chart review with expert nephrology input.
The 2020 Clinical Immuno-Oncology Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).
[Presentation title: Incidence and Prediction of Checkpoint Inhibitor Immune-Related Nephrotoxicity. Abstract 91]
ORLANDO, Fla -- February 10, 2020 -- Immune-related acute kidney injury (AKI) occurs infrequently among patients being treated with immune checkpoint inhibitors for advanced cancers, according to a study presented here at the 2020 Clinical Immuno-Oncology Symposium.
In a database of nearly 2,000 patients, immune-related AKI occurred in 14 patients and 8 cases were severe enough to warrant referral to kidney specialists, reported Jonathan Sorah, MD, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
None of the 14 patients were treated with steroids, and kidney function returned to baseline parameters in 5 patients. Two other patients improved but kidney function did not reach baseline numbers. One patient failed to improve and another was required to go on dialysis.
"Early recognition is critically important to prevent the possibility of irreversible renal damage, requiring prompt initiation of corticosteroids and nephrology consult," said Dr. Sorah. "Although clinically-significant immune-related acute kidney injury is uncommon among patients treated with immune checkpoint inhibitors, it is still likely under-recognised due to many confounding factors. High clinical suspicion should exist in patients with pre-existing autoimmune disease or a history of other immune-related adverse effects."
Two of the patients with acute kidney injury had been diagnosed with an autoimmune disorder and 9 patients with immune-related AKI also had a history of immune-related adverse effects.
Patients diagnosed with immune-related AKI were mostly men. Of the patients, 6 were being treated for non-small-cell lung cancer, 3 for melanoma, and 5 for other cancers. All patients were treated between April 2014 and December 2018. The etiology of the acute kidney injury was determined by chart review with expert nephrology input.
The 2020 Clinical Immuno-Oncology Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).
[Presentation title: Incidence and Prediction of Checkpoint Inhibitor Immune-Related Nephrotoxicity. Abstract 91]
posted by dermatica at
March 22, 2020
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home